BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25269340)

  • 21. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF).
    Sène D; Limal N; Ghillani-Dalbin P; Saadoun D; Piette JC; Cacoub P
    Rheumatology (Oxford); 2007 Jan; 46(1):65-9. PubMed ID: 16782735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.
    Cancro MP; D'Cruz DP; Khamashta MA
    J Clin Invest; 2009 May; 119(5):1066-73. PubMed ID: 19411764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases.
    Půtová I; Dostal C; Becvar R
    Ann N Y Acad Sci; 2007 Aug; 1109():275-86. PubMed ID: 17785316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
    Ritterhouse LL; Crowe SR; Niewold TB; Merrill JT; Roberts VC; Dedeke AB; Neas BR; Thompson LF; Guthridge JM; James JA
    Arthritis Rheum; 2011 Dec; 63(12):3931-41. PubMed ID: 22127709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus.
    Cavazzana I; Kumar R; Pozzari C; Ottaviani R; Fredi M; Piantoni S; Andreoli L; Tincani A; Franceschini F
    Lupus; 2019 Aug; 28(9):1074-1081. PubMed ID: 31296140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus.
    Hanly JG; Thompson K; McCurdy G; Fougere L; Theriault C; Wilton K
    J Immunol Methods; 2010 Jan; 352(1-2):147-52. PubMed ID: 19836394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
    Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
    Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
    Stohl W
    Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.
    Mariette X; Roux S; Zhang J; Bengoufa D; Lavie F; Zhou T; Kimberly R
    Ann Rheum Dis; 2003 Feb; 62(2):168-71. PubMed ID: 12525388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
    Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
    Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
    Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH
    Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
    de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
    Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
    Ezzat M; El-Gammasy T; Shaheen K; Shokr E
    Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.
    Pavón EJ; Zumaquero E; Rosal-Vela A; Khoo KM; Cerezo-Wallis D; García-Rodríguez S; Carrascal M; Abian J; Graeff R; Callejas-Rubio JL; Ortego-Centeno N; Malavasi F; Zubiaur M; Sancho J
    Cytokine; 2013 May; 62(2):232-43. PubMed ID: 23538292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population.
    Wu O; Chen GP; Chen H; Li XP; Xu JH; Zhao SS; Sheng J; Feng JB; Cai J; Fang XH; Zhang WH; Li LH; Zhang N; Li J; Li JJ; Pan FM; Wang CZ; Ye DQ
    Immunobiology; 2009; 214(5):392-402. PubMed ID: 19362685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus.
    Montiel JL; Monsiváis-Urenda A; Figueroa-Vega N; Moctezuma JF; Burgos-Vargas R; González-Amaro R; Rosenstein Y
    Scand J Rheumatol; 2010; 39(1):50-7. PubMed ID: 20132071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.